Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance
Open Access
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 7 (4), S14-S22
- https://doi.org/10.1186/ar1794
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes MellitusArchives of Internal Medicine, 2005
- Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritisAlimentary Pharmacology & Therapeutics, 2004
- Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxibThe American Journal of Cardiology, 2003
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonistsThe American Journal of Cardiology, 1991
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989